Autentificare
NeuroPsy InfoHubÎnțelege · Sprijin · ProgresCere sprijin
← Toate temele

Parkinson

Boala Parkinson și tulburări de mișcare.

64 de articole
← Toate secțiunile

Studii și știri

PublicToțiPentru oricineSpecialiști
VârstăToate vârsteleCopiiTineriAdulțiVârstnici
StudiuParkinsonÎncredere înaltă22.06.2026

Fluid and Tissue Biomarkers in Parkinson's Disease: Immunodetection versus Seed Amplification Assays

This review examines advances in Parkinson's disease biomarkers, particularly α-synuclein detection using immunodetection and emerging seed amplification assays in cerebrospinal fluid and blood. Seed amplification assays show promise as more reliable diagnostic tools with improved accuracy, representing a significant advancement toward non-invasive biomarker testing for disease diagnosis and progression monitoring.

StudiuParkinsonÎncredere înaltă22.06.2026

Neuromelanin: Role in Parkinson's Disease Pathogenesis and Therapeutic Potential

This review examines neuromelanin's complex involvement in Parkinson's disease, highlighting its paradoxical neuroprotective properties as an antioxidant alongside its harmful effects through mitochondrial dysfunction and oxidative stress when accumulated. Emerging therapeutic strategies targeting neuromelanin accumulation include antioxidant therapy, proteostasis enhancement, ion chelation, and immunotherapy, though clinical trial results remain mixed.

StudiuParkinsonÎncredere înaltă22.06.2026

Blepharoclonus in Parkinsonism: Frequency and Diagnostic Utility

This prospective study assessed the prevalence of blepharoclonus (eyelid fluttering) in 75 Parkinson's disease patients and 10 with atypical parkinsonism, finding it present in 84% of PD cases and 60% of synucleinopathy cases but absent in non-synucleinopathy parkinsonian syndromes. The findings suggest blepharoclonus may have diagnostic utility in differentiating synucleinopathy-associated parkinsonism from other parkinsonian conditions.

StudiuParkinsonÎncredere înaltă22.06.2026

New horizons in Parkinson's disease in older populations

Parkinson's disease is the second most common neurodegenerative disorder, with aging as the primary risk factor; prevalence is expected to increase globally due to population aging. Current treatments manage symptoms rather than cure the disease, and management is complicated by multiple comorbidities in older adults; this review examines disease management strategies and emerging care models aimed at improving quality of life.

StudiuParkinsonÎncredere înaltă21.06.2026

The RAB32 p.Ser71Arg Variant in Parkinsonisms: Insights from a Large Italian Cohort

A study of 4,600 Italian patients with Parkinson's disease or atypical parkinsonism identified 20 new carriers of the RAB32 p.Ser71Arg variant, which was associated with earlier disease onset (average 51 years) and good response to dopaminergic therapy. Carriers showed positive family history in 55.5% of cases, suggesting dominant inheritance patterns, with generally preserved cognitive function and mild psychiatric symptoms.

StudiuParkinsonÎncredere înaltă21.06.2026

Consensus practice recommendations for management of gastrointestinal dysfunction in Parkinson disease

This expert consensus document provides evidence-based clinical guidance on screening, diagnosis, and treatment of gastrointestinal dysfunction in Parkinson disease, a common non-motor symptom that can precede motor symptoms and significantly impact quality of life. Recommendations are organized by anatomical segments (oral cavity, esophagus, stomach, small intestine, colon) based on a modified Delphi panel approach involving movement disorder neurologists and gastroenterologists.

StudiuParkinsonÎncredere bună21.06.2026

Methamphetamine Use and Parkinson's Disease Risk: Clinical Recognition in Substance Users

Epidemiological and animal evidence indicates methamphetamine use significantly increases risk for Parkinson's disease and parkinsonism, potentially with earlier onset. Despite elevated prevalence in methamphetamine users, diagnosis is often missed due to under-detection, competing mortality risks, and confounding substance use patterns; clinicians should maintain vigilance for parkinsonian symptoms in this population.

StudiuParkinsonÎncredere bună21.06.2026

Effect of crocin on movement disorders and oxidative DNA damage in Parkinson's disease: A randomized controlled trial

This randomized controlled trial evaluated crocin (30 mg twice daily for 8 weeks) in 53 Parkinson's disease patients using movement rating scales and oxidative stress markers. The intervention showed statistically significant improvements in movement and daily activity scores, though oxidative DNA damage markers did not change significantly.

StudiuParkinsonÎncredere înaltă21.06.2026

Advanced Parkinson's Disease: Clinical, Pathologic, and Imaging Markers—A Review

This review addresses the lack of consensus definition for advanced Parkinson's disease by synthesizing clinical features (motor fluctuations, falls, cognitive decline), pathological burden markers, and neuroimaging findings associated with disease progression. The authors propose a longitudinal assessment model incorporating clinical markers and quality-of-life metrics to better characterize and predict disease trajectory in PD patients.

StudiuParkinsonÎncredere bună21.06.2026

Autopsy-Confirmed Pure Parkinson's Disease with Rapidly Progressive Dementia and Cognitive Fluctuations in a GBA Mutation Carrier

A 75-year-old woman with GBA mutation-associated Parkinson's disease initially responded well to L-Dopa but developed rapid motor decline, severe cognitive fluctuations, and dementia four years into disease course, progressing to death within one year. Autopsy confirmed pure Parkinson's pathology without concomitant Alzheimer's disease, demonstrating that sudden disease acceleration in PD does not necessarily require co-existent Alzheimer's pathology.

StudiuParkinsonÎncredere bună21.06.2026

Safinamide Effects on Sleep Architecture in Motor Fluctuating Parkinson's Disease: A Polysomnographic Study Compared to Rasagiline

A prospective study of 45 Parkinson's disease patients with sleep disturbances compared safinamide and rasagiline, two monoamine oxidase-B inhibitors. Safinamide showed superior sleep improvements including increased deep sleep (N3), better sleep efficiency, and reduced periodic limb movements, with significant improvements on sleep quality scales, while rasagiline showed minimal sleep benefit despite motor symptom improvement in both groups.

StudiuParkinsonÎncredere bună21.06.2026

Cold exposure exacerbates tremor symptoms in Parkinson's disease

Cold temperatures are known to increase tremor severity in Parkinson's disease patients, likely due to temperature sensitivity affecting basal ganglia motor control. This seasonal effect is a recognized clinical observation that patients and caregivers should monitor and manage accordingly.

StudiuParkinsonÎncredere bună21.06.2026

The Role of Artificial Intelligence and Machine Learning in Parkinson's Disease Diagnosis and Atypical Parkinsonisms

This literature review examines how machine learning techniques, particularly support vector machines and neural networks, can improve early diagnosis and progression prediction in Parkinson's disease by analyzing diverse biomarker data. The analysis demonstrates that more sophisticated machine learning approaches and ensemble models achieve higher diagnostic accuracy than simpler methods, suggesting significant potential for enhancing diagnostic capacity in movement disorders.

StudiuParkinsonÎncredere înaltă21.06.2026

Prevalence and clinical features of cervical dystonia in Parkinson's disease

This prospective study examined 301 consecutive Parkinson's disease patients and found cervical dystonia (CD) present in 9.3%, substantially higher than in the general population, with most cases developing after PD onset. CD-PD patients differed from idiopathic CD patients by being predominantly male, older, and showing milder severity with less head tremor and pain.

StudiuParkinsonÎncredere înaltă21.06.2026

Chronic Musculoskeletal Pain and Risk of Incident Parkinson's Disease: A 13-Year Longitudinal Study

This large population-based cohort study of 355,890 participants followed for 13 years examined whether chronic musculoskeletal pain increases the risk of developing Parkinson's disease and related parkinsonism disorders. Results showed a dose-response relationship: participants with more widespread chronic pain sites had progressively higher risks of incident Parkinson's disease (11-49% increased risk depending on pain extent), though the mechanisms underlying this association remain unclear.

StudiuParkinsonÎncredere bună20.06.2026

B-type natriuretic peptide in Parkinson's disease: a novel biomarker of dysautonomia

This study examines NT-proBNP levels as a potential biomarker for identifying cardiovascular autonomic dysfunction in Parkinson's disease patients. Elevated NT-proBNP was significantly associated with orthostatic hypotension and abnormal autonomic function tests, suggesting it may serve as an early indicator of cardiac autonomic denervation in PD.